Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
Agesen RM, Alibegovic AC, Andersen HU, et al. Effect of insulin degludec on frequency of severe hypoglycemia in patients with type 1 diabetes prone to nocturnal severe hypoglycemia: the HypoDeg trial. ADA 2020. Abstract 269-OR.
Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015;38:637-643.
Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261-267.
Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26:2433-2441.
Brøsen JM, Agesen RM, Alibegovic AC, et al. Nocturnal hypoglycemia with insulin degludec and glargine U100 in patients with type 1 diabetes prone to severe nocturnal hypoglycemia (HypoDeg): a CGM substudy. Presented at: American Diabetes Association (ADA) 80th Scientific Sessions, A Virtual Experience; June 12-16, 2020. Abstract 270-OR.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
Dhatariya K, Bain SC, Buse JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018;41:2229-2235.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
Hövelmann U, Brøndsted L, Kristensen NR, et al. Insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. ADA 2020. Abstract 237-OR.
Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389-400.
Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33-44.
Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723-732.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
New data on clinical outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS). Presented at: American Diabetes Association (ADA) 80th Scientific Sessions, A Virtual Experience; June 12-16, 2020.
Nishimura E, Kjeldsen T, Hubalek F, et al. Molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing. Presented at: American Diabetes Association (ADA) 80th Scientific Sessions, A Virtual Experience; June 12-16, 2020. Abstract 236-OR.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306.
Rosenstock J, Kjaersgaard MIS, Moller D, et al. Once-weekly basal insulin icodec offers comparable efficacy and safety vs. once-daily insulin glargine U100 in insulin-naïve patients with T2D inadequately controlled on OADS. Presented at: American Diabetes Association (ADA) 80th Scientific Sessions, A Virtual Experience; June 12-16, 2020. Abstract 238-OR.
Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243-254.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864-2883.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
Yki-Järvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142-1149.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Anne L. Peters, MD

Professor
Keck School of Medicine
Director
Clinical Diabetes Programs
University of Southern California
Los Angeles, United States

Disclosures

Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Livongo; MannKind Corporation;Novo Nordisk; Sanofi; Pendulum Therapeutics
Received grants for clinical research from: Abbott Laboratories; Dexcom, Inc.; vTvTherapeutics
Owns stock, stock options, or bonds from: Livongo; Mellitus Health; Omada Health; Pendulum Therapeutics

Editors

Philippa M. Berman, BA(Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA(Hons), MBBS, has disclosed no relevant financial relationships.

Zach Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zach Hartman, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?

Authors: Anne L. Peters, MD
CPD Released: 7/14/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 7/14/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK diabetologists and endocrinologists, cardiologists, and primary care physicians.

The goal of this activity is to raise awareness of up-to-date scientific and clinical data in the prevention of microvascular complications of diabetes.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Key scientific and clinical data with respect to the prevention of microvascular complications of diabetes

Disclosures

Faculty

Anne L. Peters, MD

Professor
Keck School of Medicine
Director
Clinical Diabetes Programs
University of Southern California
Los Angeles, United States

Disclosures

Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Livongo; MannKind Corporation;Novo Nordisk; Sanofi; Pendulum Therapeutics
Received grants for clinical research from: Abbott Laboratories; Dexcom, Inc.; vTvTherapeutics
Owns stock, stock options, or bonds from: Livongo; Mellitus Health; Omada Health; Pendulum Therapeutics

Editors

Philippa M. Berman, BA(Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA(Hons), MBBS, has disclosed no relevant financial relationships.

Zach Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zach Hartman, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?

Authors: Anne L. Peters, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 7/14/2020

Valid for credit through: 7/14/2021, 11:59 PM EST

processing....

Video quality may be reduced from our standard offering due to efforts to honor COVID-19 hygienic practices.

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Anne L. Peters, MD

Editors

Philippa M. Berman, BA(Hons), MBBS

Zach Hartman, PhD

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Stephanie Corder, ND, RN, CHCP

CPD

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?

Target Audience and Goal Statement

Disclosures

Faculty

Anne L. Peters, MD

Editors

Philippa M. Berman, BA(Hons), MBBS

Zach Hartman, PhD

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Stephanie Corder, ND, RN, CHCP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?